Explore

Trendline Trendline
Passkey Therapeutics Appoints New Chief Medical Officer to Enhance Drug Combination Platform

Passkey Therapeutics Appoints New Chief Medical Officer to Enhance Drug Combination Platform

Passkey Therapeutics Appoints New Chief Medical Officer to Enhance Drug Combination Platform
Trendline Trendline
Passkey Therapeutics Appoints New Chief Medical Officer to Advance Drug Combination Platform

Passkey Therapeutics Appoints New Chief Medical Officer to Advance Drug Combination Platform

Passkey Therapeutics Appoints New Chief Medical Officer to Advance Drug Combination Platform
Trendline Trendline
Passkey Therapeutics Appoints New CMO to Lead Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Lead Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Lead Drug Combination Platform
Trendline Trendline
Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements
Trendline Trendline
Harbour BioMed Advances AI-Enabled Drug Candidate LET003 for Obesity Treatment

Harbour BioMed Advances AI-Enabled Drug Candidate LET003 for Obesity Treatment

Harbour BioMed Advances AI-Enabled Drug Candidate LET003 for Obesity Treatment
Trendline Trendline
Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development
Trendline Trendline
Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins
Trendline Trendline
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead
Trendline Trendline
CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results
Trendline Trendline
Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial
Trendline Trendline
CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership

CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership

CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership